Background Polymorphisms in genes encoding transport proteins and metabolizing
enzymes involved in tacrolimus (TAC) disposition may be important sources of individual …

Aims Tacrolimus (TAC) is one of the most successful immunosuppressive drugs in
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …

Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to
tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & …

Background: Tacrolimus (TAC), acting as a calcineurin inhibitor, is an immunosuppressant
widely used after kidney transplantation. TAC requires blood concentration monitoring due …

Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G> A, CYP3A5* 3;
14690A> G, CYP3A5* 6) and drug transporter ABCB1 (1236C> T; 2677G> T/A; 3435C> T) …

The clinical use of tacrolimus (Tac) is complicated by the large inter-individual variability in
its pharmacokinetics as well as by chronic adverse effects on renal function. The main goal …

We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …

Tacrolimus has a narrow therapeutic window and a wide interindividual variation in its
pharmacokinetics. The cytochrome P450 3A (C YP3A) and the ATP-binding cassette B1 …

Background. A body-weight-based dose of tacrolimus often results in marked individual
diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) …

Background: The highly pharmacokinetic variability of tacrolimus makes it difficult to adjust
the dose. In the current study, we investigated the influence of gene polymorphisms and …